Drugs from Nature: Targets, Assay Systems and Leads - read free eBook in online reader or directly download on the web page. Select files or add your book in reader. Download and read online ebook Drugs from Nature: Targets, Assay Systems and Leads write by Madhathilkovilakathu Haridas. This book was released on . Drugs from Nature: Targets, Assay Systems and Leads available in PDF, EPUB and Kindle.
Drugs from Nature: Targets, Assay Systems and Leads
Drugs from Nature: Targets, Assay Systems and Leads - read free eBook in online reader or directly download on the web page. Select files or add your book in reader. Download and read online ebook Drugs from Nature: Targets, Assay Systems and Leads write by Madhathilkovilakathu Haridas. This book was released on 2024-03-07. Drugs from Nature: Targets, Assay Systems and Leads available in PDF, EPUB and Kindle. This book provides an overview of the drug discovery process from natural sources such as plants and microbes. While technological advances have streamlined the drug discovery process, enhancing the throughput and success rates, the structural features of natural products remain the primary reference for small-molecule drug discovery. Focusing on the drug targets blocked/altered by natural/nature-inspired molecules, it covers how potential drug leads are screened and identified using appropriate assay systems, and the current status of drugs identified using such approaches. State-of-the-art approaches in target identification, assay development, and lead identification have also been discussed in detail. Other topics included are targets and leads in inflammation, cancer, reproductive medicine, cardiovascular and neuromuscular ailments, and infectious diseases as well as the challenges in translating drug leads into clinically viable drugs. This volume serves as a handbook for researchers in phytochemistry and drug discovery, and as a reference for researchers and students of applied biology.
Evaluation of Enzyme Inhibitors in Drug Discovery
Evaluation of Enzyme Inhibitors in Drug Discovery - read free eBook in online reader or directly download on the web page. Select files or add your book in reader. Download and read online ebook Evaluation of Enzyme Inhibitors in Drug Discovery write by Robert A. Copeland. This book was released on 2005-04-01. Evaluation of Enzyme Inhibitors in Drug Discovery available in PDF, EPUB and Kindle. Vital information for discovering and optimizing new drugs "Understanding the data and the experimental details that support it has always been at the heart of good science and the assumption challenging process that leads from good science to drug discovery. This book helps medicinal chemists and pharmacologists to do exactly that in the realm of enzyme inhibitors." -Paul S. Anderson, PhD This publication provides readers with a thorough understanding of enzyme-inhibitor evaluation to assist them in their efforts to discover and optimize novel drug therapies. Key topics such as competitive, noncompetitive, and uncompetitive inhibition, slow binding, tight binding, and the use of Hill coefficients to study reaction stoichiometry are all presented. Examples of key concepts are presented with an emphasis on clinical relevance and practical applications. Targeted to medicinal chemists and pharmacologists, Evaluation of Enzyme Inhibitors in Drug Discovery focuses on the questions that they need to address: * What opportunities for inhibitor interactions with enzyme targets arise from consideration of the catalytic reaction mechanism? * How are inhibitors evaluated for potency, selectivity, and mode of action? * What are the advantages and disadvantages of specific inhibition modalities with respect to efficacy in vivo? * What information do medicinal chemists and pharmacologists need from their biochemistry and enzymology colleagues to effectively pursue lead optimization? Beginning with a discussion of the advantages of enzymes as targets for drug discovery, the publication then explores the reaction mechanisms of enzyme catalysis and the types of interactions that can occur between enzymes and inhibitory molecules that lend themselves to therapeutic use. Next are discussions of mechanistic issues that must be considered when designing enzyme assays for compound library screening and for lead optimization efforts. Finally, the publication delves into special forms of inhibition that are commonly encountered in drug discovery efforts, but can be easily overlooked or misinterpreted. This publication is designed to provide students with a solid foundation in enzymology and its role in drug discovery. Medicinal chemists and pharmacologists can refer to individual chapters as specific issues arise during the course of their ongoing drug discovery efforts.
Phenotypic Drug Discovery
Phenotypic Drug Discovery - read free eBook in online reader or directly download on the web page. Select files or add your book in reader. Download and read online ebook Phenotypic Drug Discovery write by Beverley Isherwood. This book was released on 2020-12-09. Phenotypic Drug Discovery available in PDF, EPUB and Kindle. Phenotypic drug discovery has been highlighted in the past decade as an important strategy in the discovery of new medical entities. How many marketed drugs are derived from phenotypic screens? From the most recent examples, what were the factors enabling target identification and validation? This book answers these questions by elaborating on fundamental capabilities required for phenotypic drug discovery and using case studies to illustrate approaches and key success factors. Written and edited by experienced practitioners from both industry and academia, this publication will equip researchers with a thought-provoking guide to the application and future development of contemporary phenotypic drug discovery for clinical success.
Improving and Accelerating Therapeutic Development for Nervous System Disorders
Improving and Accelerating Therapeutic Development for Nervous System Disorders - read free eBook in online reader or directly download on the web page. Select files or add your book in reader. Download and read online ebook Improving and Accelerating Therapeutic Development for Nervous System Disorders write by Institute of Medicine. This book was released on 2014-02-06. Improving and Accelerating Therapeutic Development for Nervous System Disorders available in PDF, EPUB and Kindle. Improving and Accelerating Therapeutic Development for Nervous System Disorders is the summary of a workshop convened by the IOM Forum on Neuroscience and Nervous System Disorders to examine opportunities to accelerate early phases of drug development for nervous system drug discovery. Workshop participants discussed challenges in neuroscience research for enabling faster entry of potential treatments into first-in-human trials, explored how new and emerging tools and technologies may improve the efficiency of research, and considered mechanisms to facilitate a more effective and efficient development pipeline. There are several challenges to the current drug development pipeline for nervous system disorders. The fundamental etiology and pathophysiology of many nervous system disorders are unknown and the brain is inaccessible to study, making it difficult to develop accurate models. Patient heterogeneity is high, disease pathology can occur years to decades before becoming clinically apparent, and diagnostic and treatment biomarkers are lacking. In addition, the lack of validated targets, limitations related to the predictive validity of animal models - the extent to which the model predicts clinical efficacy - and regulatory barriers can also impede translation and drug development for nervous system disorders. Improving and Accelerating Therapeutic Development for Nervous System Disorders identifies avenues for moving directly from cellular models to human trials, minimizing the need for animal models to test efficacy, and discusses the potential benefits and risks of such an approach. This report is a timely discussion of opportunities to improve early drug development with a focus toward preclinical trials.
